Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Outlook Therapeutics, a biopharmaceutical company focused on developing the first FDA-approved ophthalmic formulation of bevacizumab, will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:40 AM ET. The President & CEO, C. Russell Trenary III, will lead the presentation, followed by one-on-one virtual meetings with investors. A live video webcast of the presentation will be available on the company's investor website, with a replay accessible for 90 days. Outlook aims to commercialize ONS-5010 as the first FDA-approved formulation for retinal diseases.

Live video webcast presentation on Friday, February 18th at 10:40 AM ET

ISELIN, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President & Chief Executive Officer will present at the virtual 11^th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 10:40 AM ET.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live video webcast of the presentation will be available on the Events page of the Investors section of Outlook Therapeutics’ website (outlooktherapeutics.com). A webcast replay will be available following the live presentation and will be accessible for 90 days.

About Outlook Therapeutics, Inc.        

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:
Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:       
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
OTLK@jtcir.com 

FAQ

What is Outlook Therapeutics presenting at the SVB Leerink Global Healthcare Conference on February 18, 2022?

Outlook Therapeutics will present its development of ONS-5010, the first FDA-approved ophthalmic formulation of bevacizumab, at the SVB Leerink Global Healthcare Conference.

Who is the CEO of Outlook Therapeutics presenting at the conference?

C. Russell Trenary III, the President & CEO of Outlook Therapeutics, will present at the conference.

How can I watch the live webcast of Outlook Therapeutics' presentation?

The live video webcast can be viewed on the Events page of Outlook Therapeutics’ investor website.

When will the webcast replay of the Outlook Therapeutics presentation be available?

The webcast replay will be available for 90 days following the live presentation.

What is the significance of ONS-5010 for Outlook Therapeutics?

ONS-5010 is expected to be the first FDA-approved ophthalmic formulation of bevacizumab for treating retinal diseases, which Outlook Therapeutics plans to commercialize globally.